Pentoxifylline-supplemented cryoprotectant improves human sperm motility after cryopreservation

Area of Science:

• Reproductive Biology
• Sperm Cryopreservation

Background:

• Sperm cryopreservation is crucial for assisted reproductive technologies.
• Optimizing cryoprotective media is essential for maintaining sperm viability and function post-thaw.

Purpose of the Study:

• To investigate the effect of pentoxifylline, a phosphodiesterase inhibitor, on human sperm cryopreservation.
• To determine the optimal concentration of pentoxifylline for improving post-thaw sperm motility and acrosome morphology.

Main Methods:

• Human spermatozoa from 15 donors were cryopreserved with varying concentrations of pentoxifylline (0, 1, 3, 10 mM).
• Sperm motility (progressive and total) and acrosome morphology were assessed post-thaw.
• Acrosome morphology was evaluated using fluorescein-conjugated concanavalin A lectin staining.

Main Results:

• 1 mM pentoxifylline significantly improved post-thaw progressive motility (15.3% to 23.1%) and total motility (27.4% to 38.2%) without affecting acrosome integrity.
• The beneficial effects of 1 mM pentoxifylline on sperm motility persisted for 6 hours post-thaw.
• 10 mM pentoxifylline significantly reduced acrosome morphology (29.0% to 21.0%) but did not impact sperm motility.

Conclusions:

• Supplementing cryoprotectant with 1 mM pentoxifylline is beneficial for human sperm cryopreservation, enhancing motility without compromising acrosomal integrity.
• Acrosome morphology assessment is critical for detecting subtle detrimental effects of cryoprotectant additives.
• Optimal pentoxifylline concentration for cryopreservation is 1 mM, differing from previous studies.